Details of the Drug
General Information of Drug (ID: DMKCBIL)
Drug Name |
6-chloro-1H-indazole
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
6-Chloro-1H-indazole; 698-25-9; 6-Chloroindazole; 1H-Indazole, 6-chloro-; 1H-INDAZOLE,6-CHLORO-; CHEMBL392184; VUZQHUVRBPILAX-UHFFFAOYSA-N; AK-27924; 6-chloroazaindole; 6-chloro-indazole; NSC92743; PubChem20592; AC1L9DR4; SCHEMBL3533806; SCHEMBL16523332; CTK2F6854; DTXSID70329119; MolPort-000-002-984; HMS1629J03; 6-Chloro-1H-indazole, AldrichCPR; ACT06345; ZINC4878475; BCP00929; EBD48419; NSC-92743; BDBM50209236; BBL101057; STL554851; ANW-50721; FCH835101; AKOS005256021; AKOS024124978; RP01765; CS-W005017; VI20061; FS-2891; QC-2958; PB34228
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 152.58 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.9 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||